---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-24-000052"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:18:04.467767+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q3 product revenue $420M (+34%); GAAP EPS -$0.87, guidance reaffirmed

## Summary
- Global net product revenues $420M, up 34% YoY; TTR (ONPATTRO+AMVUTTRA) $309M, Rare (GIVLAARI+OXLUMO) $111M.
- GAAP net loss $111.6M ($0.87 loss per share) vs. prior-year net income $147.8M ($1.18); Non-GAAP loss $64.2M ($0.50).
- Submitted sNDA in U.S. and Type II Variation in EU for vutrisiran in ATTR-CM using Priority Review Voucher; potential U.S. launch early 2025.
- Positive Phase 1 mivelsiran data in Alzheimer's: >90% sAPPβ lowering after second dose; no new safety signals. Ph2 planned year-end.
- Suspended ALN-KHK development for type 2 diabetes; appointed Robert Hesslein as Chief Legal Officer.

## SEC filing metadata
- accession: 0001178670-24-000052
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000052/0001178670-24-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000052/alny-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-24-000052
- JSON: https://secwatch.observer/filing/0001178670-24-000052.json
- Plain text: https://secwatch.observer/filing/0001178670-24-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.